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Summary: The effect of androgen deprivation on lipoprotein profile and cardiovascular risk in men with advanced
prostatic carcinoma is a matter of controversy. We describe an experimental model to evaluate the effects of
orchidectomy and oestrogen and luliberin analogue administration on lipoprotein profiles in male Sprague-Dawley
rats. Eighty rats were divided into three treatment groups and a control group. Results were compared with the
scanty human data found in the literature. The oestrogen group was that which showed more differences compared
with the control group, but its lipoprotein profile differed from that obtained in humans. Orchidectomy and luliberin
analogue groups showed fewer differences than the oestrogen group, but a non-favourable lipoprotein profile in
terms of cardiovascular risk was observed. There were important differences between humans and rats with regard
to lipoprotein profile, suggesting that rats are probably not a good model for the study of atherogenic risk.
Introduction
Androgen deprivation was introduced over 50 years ago
by Huggins & Hodges (1) for the treatment of prostatic
carcinoma. This effective mode of treatment is adminis-
tered in almost all cases of prostatic cancer considered
to be surgically incurable. Orchidectomy, oestrogens and
luliberin analogues are effective tools for hormone treat-
ment in advanced disease, and are used interchangeably
according to patient or physician preferences since their
clinical effects are similar in patients with hormone-sen-
sitive prostatic cancer (2). These three forms of andro-
gen deprivation therapy act at different levels in the met-
abolic pathway of androgen synthesis and lipoprotein
metabolism which change plasma lipoprotein profile.
Nowadays, prostatic carcinoma is perhaps the most fre-
quent cancer in men with an incidence that increases
with age parallel to that of cardiovascular disease. Thus,
we presupposed that hormone treatment, depending on
its level of interference and lipoprotein changes, might
influence the risk of atherosclerotic cardiovascular dis-
ease (3-5).
The effect of steroid hormones on lipoprotein metabo-
lism described in extensive studies on oral contracep-
tives and oestrogen replacement therapy in postmeno-
pausal women are well known (6), but have scarcely
been studied in men, bearing in mind the differences in
plasma lipoprotein patterns between men and women.
Orchidectomy was the first mode of androgen depriva-
tion (1) and luliberin analogues have recently been intro-
duced in the treatment of prostatic carcinoma (7, 8).
Several authors have described their effects on plasma
lipoprotein profiles in men with advanced prostatic car-
cinoma, but most of these studies were incomplete and
not randomized (5, 9—12).
Although lipoprotein metabolism in rats can not be ex-
trapolated to humans, the aim of the present study was
to investigate the effects of orchidectomy, oestrogen ad-
ministration and luliberin analogue therapy on lipopro-
tein profiles in rats. To our knowledge, experimental
studies on plasma lipoprotein profiles following andro-
gen deprivation in Sprague-Dawley rats have not been
previously reported.
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Materials and Methods
Animals
Four groups of 20 male Sprague-Dawley rats (Oncins France Strain
A-OFA rat-Prolabor Laboratories, Barcelona, Spain) aged from
6-8 weeks with a body weight of 200-275 g. were studied.
Control group
Twenty rats were kept in metabolic cages with an homogeneous
and regular diet of standard Pecoris rat chow (Prolabor Laborator-
ies) and water ad libitum for eight weeks. They were then fasted
for eight hours, weighed and anaesthetized with ketamine 250 mg
(2.5 ml) + diacepam 20 mg (4ml) + atropine 1 mg (1 ml) at a
dose of 0.5 ml/100 mg of weight (i.m.)- Middle laparotomy was
performed, a catheter inserted in the aorta artery and all its blood
drawn for testosterone and lipoprotein analysis.
Lipoprotein analysis was performed by processing blood samples
by centrifugation at 3000 min"1 for 10 min. The serum obtained
was used to measure testosterone levels, serum cholesterol, serum
triacylglycerols, cholesterol, triacylglycerols and proteins in very
low density lipoproteins (VLDL), intermediate density lipoproteins
(1DL), low density lipoproteins (LDL) and high density lipopro-
teins (HDL). YLDL fraction (d < 1.006 kg/dm3) was isolated by
preparative ultracentrifugation in a Centrikon ultracentrifugal
(Kontron Instruments, Milan, Italy) using a TFT 50.38 rotor
(Kontron Instruments). The remaining lipoproteins (IDL: 1.006
< d < 1.019 kg/dm3; LDL: 1.019 < d < 1.063 kg/dm3; and HDL:
d > 1.063 kg/dm3) were isolated by density gradient ultracentrifu-
gation in a TST 41.14 rotor. Serum cholesterol, serum triacylglyc-
erols, cholesterol and triacylglycerols of lipoprotein fractions were
measured enzymatically using a selective multichannel analyzer
Eris (Eppendorf, Hamburg, Germany) and standardized with con-
trol sera (Qualitrol, Merck, Frankfurt, Germany). Proteins of each
isolated fraction were determined by a colorimetric method.
Orchidectomy group
Twenty rats were kept in metabolic cages with an homogeneous
and regular diet of standard Pecoris rat chow (Prolabor Laborator-
ies) and water ad libitum for one week to become adapted. They
were then weighed, and anaesthetized following the protocol de-
scribed above, and bilateral orchidectomy was performed. The rats
were kept in metabolic cages in the same conditions for a further
seven weeks, being weighed, fasted for eight hours and blood sam-
ples obtained as before for testosterone (in all samples at levels of
castration < 0.2 μg/l) and lipoprotein analysis.
Oestrogens group
Twenty rats were kept in metabolic cages with an homogeneous
and regular diet of standard Pecoris rat chow (Prolabor Laborator-
ies) and water ad libitum for one week to become adapted. They
were then injected subcutaneously with fosfestrol (stilboestrol di-
phosphate, Honvan®) 3 mg/kg daily for five weeks, being weighed,
fasted for eight hours and blood samples obtained as before for
testosterone (in all samples at levels of castration < 0.2
 μβ/1) and
lipoprotein analysis. Fosfestrol was chosen for this study because
of its use m clinical practice at our Department.
Luliberin analogue group
Twenty rats were kept in metabolic cages with an homogeneous
and regular diet of standard Pecoris rat chow (Prolabor Laborator-
ies) and water ad libitum for one week to become adapted They
were then injected subcutaneously with triptoreline (Decapeptyl®)
300 pgfcg every 28 days for eight weeks (two doses), being
weighed, fasted for eight hours and blood samples obtained as be
fore for testosterone (in all samples at levels of castration < 0 2
μg/l) and lipoprotein analysis. Triptoreline was chosen for this
study because of its use in clinical practice at our Department.
Statistical analysis
Normal distribution of continuous variables was confirmed by the
Kolmogorov-Smirnoff test. Inter-group comparison was made by
analysis of variance used factorially, and intra-group differences
were tested by the Fisher PLSD test.
Results
Serum cholesterol and triacylglycerols and cholesterol,
triacylglycerols and proteins in VLDL, IDL, LDL and
HDL are shown in table 1. Significant differences were
observed in serum cholesterol (p < 0.0001), for which
the oestrogen group showed a statistically significant
decrease compared with the other groups (p < 0.05).
Likewise, the luliberin analogue group showed an
increase in serum cholesterol versus the control group
(p < 0.05). Significant differences were observed in
VLDL-cholesterol (p < 0.042), with a fall in the oestro-
gen group compared with the control group (p < 0.05).
Significant differences were also found in IDL-choles^
terol (p < 0.0001), with increases in all three treatment
groups versus the control group (p < 0.05). IDL-pro-
teins showed significant differences (p < 0.0128), with
increases in the orchidectomy group versus the control
and oestrogen groups (p < 0.05). LDL-cholesterol
showed significant differences (p < 0.0038), with in-
creases in the luliberin analogue group versus the con-
trol and oestrogen groups (p < 0.05), and the orchidec-
tomy group versus the oestrogen group (p < 0.05). Sig-
nificant differences were also observed in LDL-proteins
(p < 0.001), with increases in the orchidectomy and luli-
berin analogue groups compared with the control and
oestrogen groups (p < 0.05). HDL-cholesterol showed
significant differences (p < 0.0001), with a large fall in
the oestrogen group versus all the other groups
(p < 0.05). HDL-proteins showed significant differ-
ences (p < 0.0001), with a large increase in the oestro-
gen group versus the other three groups (p < 0.05), and
increases in the orchidectomy group versus the control
group (p < 0.05).
Discussion
Serum lipoprotein composition in rats differs signifi-
cantly according to the rat strain. Furthermore, the find-
ing of great variations in lipoprotein composition m ani-
mals of the same strain is noteworthy. These discrepan-
cies are difficult to explain solely on the basis of nutri-
tional status, and are probably related to pooling of small
blood samples from several animals (13-16). This
drawback was obviated in the Jwfesent study since lipo-
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Tab. 1 Lipoprotein values.
Serum
Cholesterol
Triacylglycerols
VLDL
Cholesterol
Triacylglycerols
Proteins
IDL
Cholesterol
Triacylglycerols
Proteins
LDL
Cholesterol
Triacylglycerols
Proteins
HDL
Cholesterol
Triacylglycerols
Proteins
Serum/HDL
Cholesterol ratio
LDL/HDL
Cholesterol ratio
The results are given as
Control
2.13(0.45)
1.21 (0.81)
0.24(0.12)
0.67 (0.65)
0.34 (0.39)
0.06 (0.02)
0.25(0.19)
0.03 (0.03)
0.47 (0.25)
0.12(0.08)
0.08 (0.05)
1.12(0.26)
0.13(0.20)
0.76(0.12)
0.04(0.01)
0.01(0.01)
mean ± SD mmol/1
Orchidectomy
2.38 (0.59)
1.24(0.74)
0.20 (0.20)
0.54 (0.36)
0.34 (0.35)
0.12(0.05)
0.41 (0.35)
0.06 (0.05)
0.53 (0.24)
0.08(0.11)
0.19(0.11)
1.18(0.36)
0.07 (0.04)
0.89(0.21)
0.05 (0.01)
0.01 (0.01)
(lipids) and g/1
Oestrogens
1.02(0.32)
0.33 (0.59)
0.10(0.02)
0.30 (0.26)
0.49 (0.28)
0.12(0.03)
0.23 (0.21)
0.03 (0.01)
0.29 (0.25)
0.05 (0.04)
0.09 (0.2)
0.43 (0.05)
0.08 (0.05)
1.32(0.19)
0.06(0.01)
0.01 (0.01)
(proteins).
Luliberin
2.51 (0.37)
1.29(1.20)
0.15(0.04)
0.47 (0.52)
0.55 (0.36)
0.13(0.03)
0.42 (0.45)
0.05 (0.02)
0.64 (0.25)
0.11 (0.13)
0.17(0.02)
1.24(0.14)
0.11 (0.08)
0.81 (0.08)
0.05(0.01)
0.01 (0.01)
P
p < 0.0001°
NS
p < 0.0426
NS
NS
p<0.0001c
NS
p<0.012d
p < 0.003e
NS
p < 0.0001 f
p < O.OOOie
NS
p<0.0001h
NS
NS
Oestrogen group significantly differs from all other groups
(p < 0.05). Luliberin analogue group significantly differs from
control group (p < 0.05).
Oestrogen group significantly differs from control group
(p < 0.05).
Control group significantly differs from all other groups
(p < 0.05).
Orchidectomy group significantly differs from control and
oestrogen groups (p < 0.05).
Luliberin analogue group significantly differ from control and
oestrogen groups (p < 0.05). Orchidectomy group significantly
differs from oestrogen group (p < 0.05).
Orchidectomy and luliberin analogue groups significantly dif-
fer from control and oestrogen group (p < 0.05).
Oestrogen group significantly differs from all other groups
(p < 0.05).
Oestrogen group significantly differs from all other groups
(p < 0.05). Orchidectomy group significantly differs from con-
trol group (p < 0.05).
protein analysis was performed in each rat. Previous
data do not permit comment on any association between
lipoprotein profile and sex. On the contrary, age is a
major factor in determining circulating lipoprotein
levels (17).
Serum lipoprotein composition and laboratory methods
in male Sprägüe-Dawiey rats have been thoroughly re-
ported (13, 16, 19, 21-27), although quantitative serum
lipoprotein analysis in the Sprague-Dawiey strain have
barely been defined. The results described by De Pury
et al. (18) a&a Lasser et al. (19) concur with ours, which
differ from those obtained in other strains such as the
Wistar (15) and Holtzman (20).
In animals, the largest amount of cholesterol is carried
by HDL (15) as we found in the Sprague-Dawiey strain
(50%). Also, we observed that total serum cholesterol is
much lower than in humans, as well as LDL-cholesterol,
which suggests that rats are probably not a good model
for studying atherogenic risk. This statement is con-
firmed by the atherogenic ratio (serum cholesterol/HDL-
cholesterol or LDL-cholesterol/HDL-cholesterol), which
reflects the risk of cardiovascular disease (28, 29). In
the present study serum cholesterol/HDL-cholesterol ra-
tio was 1.93 ± 0.40, and LDL-cholesterol/HDL-choles-
terol ratio was 0.41 ± 0.18. Since a serum cholesterol/
HDL-cholesterol ratio of 3.5 or less is considered opti-
mal in humans and an indicator of low cardiovascular
risk (30), it may in part explain why rats rarely suffer
from atherosclerosis.
Orchidectomy has scarcely been studied in relation to
lipoprotein profile in men with advanced prostatic carci-
noma. Increases in serum cholesterol (5, 11, 12), LDL-
apolipoprotein B (11) and serum and LDL-triacylglycer-
ols (12) have been described. In rats, we observed an
increase in IDL-cholesterol, IDL-proteins, HDL-proteins
and LDL-proteins. In general, no great variations were
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noted compared with the control group. Perhaps the
increase in LDL-apolipoprotein B may be consistent
with a rise in the number of LDL particles, since each
LDL particle contains only one apolipoprotein B. mole-
cule (31), which leads to increased cardiovascular risk.
The influence of oestrogens on lipoprotein profiles has
been widely studied and shows differences between the
effects of endogenous and exogenous gonadal hor-
mones, between men and pre and postmenopausal
women, and depending on the composition and dosage
of the hormone administered (6). Synthetic and conju-
gated oestrogens increase plasma VLDL and total tria-
cylglycerols by enhancing their hepatic synthesis, partic-
ularly large VLDL particles which are directly catabo-
lized by the liver rather than delipidated to small VLDL
and LDL, and their elevation may thus be less athero-
genic than other triacylglycerol-rich lipoproteins. A fur-
ther main effect of oestrogens is to decrease LDL-cho-
lesterol levels by increasing their clearance rate (increas-
ing liver LDL receptors activity). Finally, the third most
important effect of oestrogens is to raise HDL and
HDL2-cholesterol and apolipoprotein A-I levels by in-
hibiting hepatic lipase activity (32-36). In the present
study, decreases in serum cholesterol, VLDL-choles-
terol, LDL-cholesterol (although without statistical sig-
nificance) and HDL-cholesterol, together with increases
in IDL-cholesterol and HDL-proteins have been ob-
served in oestrogen treated rats compared with those of
the control group.
Although no benefits were observed in the first large
study of oestrogens and cardiovascular risk (37) with
oestrogen therapy, the majority of other large studies
conclude that oestrogen administration is associated
with a reduced incidence of coronary heart disease and
cardiovascular mortality (38-40), A similar lipoprotein
profile is found in men with prostatic carcinoma
following oestrogen therapy (5, 11, 12, 41).
Luliberin analogues have recently been introduced as a
therapy for androgen deprivation in.-prostatic carcinoma,
but their effects on lipoprotein profiles still have
scarcely been investigated. Moorjani et al. (10, 11) have
published two controversial, non-prospective and non-
randomized studies, which showed increases in HDL-
cholesterol and apolipoprotein A-I, with raised serum
cholesterol in the former and no changes in serum cho-
lesterol in the latter. On the other hand, Paisey et al.
(9) have reported no changes in lipoprotein profiles and
Gillatt et al. (42) have described an increase in total
cholesterol levels. Therefore, the effects of luliberin ana-
logues on cardiovascular risk remains controversial.
Using luliberin analogues in rats, we have observed in-
creases in serum cholesterol, LDL-cholesterol, IDL-cho-
lesterol and LDL-proteins compared with the control
group, which represents a non-favorable lipoprotein pro-
file in terms of cardiovascular risk.
Finally, the increase in IDL-cholesterol observed invajl
treatment groups compared with control group was re-
markable, since recent studies point to the atherogenic
properties of IDL particles in humans, instead of triacyl-
glycerol-rich particles (36).
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